immuno-oncology

BioNTech
Biotech

BioNTech sets survival standard in hard-to-treat cancer

BioNTech linked gotistobart to a median OS of 18.5 months, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
Nick Paul Taylor Sep 14, 2026 4:15am
paper airplane

Inhibrx says OX40 agonist’s durability confirmed by ph. 2 win

Sep 8, 2026 10:22am
Moderna ESMO

Merck-Moderna vaccine data spur talk of Keytruda-like impact

Aug 20, 2026 9:25am
ESMO AstraZeneca

AstraZeneca ends phase 3 cancer trial as bispecific underwhelms

Aug 17, 2026 4:45am
Person throwing piece of paper into full waste bin
Favicon Fierce Pharma

Nature retracts provocative PD-1 time-of-day study

Jun 24, 2026 11:00am
Golfer devastated after just barely missing a putt

Regeneron rocked by failure as melonama drug can't beat Keytruda

May 18, 2026 4:40am